PSI CRO Selected to Lead a Major Clinical Trial Program for POINT...
pharmatechoutlook

PSI CRO Selected to Lead a Major Clinical Trial Program for POINT Biopharma

By Pharma Tech Outlook | Tuesday, June 02, 2020

Christian Buhlmann, Head of Business Development, Europe and APAC

PSI CRO has been selected to lead POINT Biopharma's phase 3 clinical study of a radiotherapeutic for treating prostate cancer 

FREMONT, CA: PSI CRO gets selected by POINT Biopharma to manage its phase 3 clinical study of PNT2002, a 177Lu-PSMA radiotherapeutic for the treatment of metastatic castrate-resistant prostate cancer. 

"PSI CRO is a leading, full-service, global clinical research organization, and is excited to be selected as the preferred provider to POINT to lead this important study," says Tibor Kovacs, Head of North American Operations, PSI CRO. 

POINT Biopharma is rigorously working to transform radiopharmaceutical drug development and its commercialization. "Choosing the right CRO partner is crucial to the success of any trial, but even more so in nuclear medicine studies," stated POINT Biopharma's Chief Commercial Officer, Michael Gottlieb. While discussing PSI CRO, which is recognized as one of the top CROs among APAC Companies By APAC CIO Outlook, Micheal Gottlieb states, "PSI CRO has a proven track record of delivering radiopharmaceutical studies on time and budget, and that means getting our product to market quickly and introducing new competitive oncology therapies to the Novartis radioligand portfolio." 

PSI CRO has been one of the leading full-service global Contract Research Organization. It has an impressive track record of allowing its sponsors to fulfill requirements related to their studies on time and is considered to build the most trusted relationships. The company has a robust foundational mechanic with biotech sponsors, of which almost 90 percent of its clientele are repeat customers and referrals.

"POINT is excited to partner with PSI CRO and launches a phase 3 registration trial of PNT2002 in prostate cancer patients," says Joe McCann, CEO of POINT Biopharma. "This ground-breaking trial design will offer physicians and patients with new options. Enrollment is expected in the fourth quarter of 2020." 

PSI's global reach program helps successful fulfillment of clinical trials across multiple countries and continents and is famous for being highly selective about the work that they pursue. 

Weekly Brief

Read Also